Evidence map›Paper›PMID 41593390›Full record

ArticleJournal of cancer research and clinical oncology2026

Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center.

Tamara Rordorf, Panagiotis Balermpas, Tomas Brezina, Martina A Broglie, Sandra N Freiberger, Kristian Ikenberg, Anja Lorch, Gregoire B Morand, Simon A Mueller, Martin Zoche and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tamara RordorfDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091, Zurich, Switzerland. tamara.rordorf@usz.ch.
Panagiotis BalermpasDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Tomas BrezinaDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.
Martina A BroglieDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Sandra N FreibergerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Kristian IkenbergDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Anja LorchDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.
Gregoire B MorandDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Simon A MuellerDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Martin ZocheDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Joerg BeyerDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
Niels J RuppDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSalivary gland carcinomas (SGC) are rare, heterogenous malignancies with limited treatment options in recurrent or metastatic (r/m) disease. We investigated the impact of immunohistochemical and molecular markers on treatment choice and patient outcomes.

methodsWe retrospectively investigated clinical, pathological and molecular characteristics of 51 patients (pts) with r/m SGC treated at the University Hospital Zurich between 2010 and 2024. Immunohistochemical and molecular profiles were evaluated in respect to treatment selection, response and survival.

resultsSalivary duct carcinoma (SDC) and adenoid-cystic carcinoma (AdCC) were the most common subtypes. In the SDC group, in 15/20 pts personalized first-line treatment based on immunohistochemical or molecular findings resulted in higher response rates and longer duration of response compared to chemotherapy. In 20 pts of the AdCC group, no actionable alterations were identified. Yet, pts in this group demonstrated the longest overall survival despite low response rates. Among 11 pts with other subtypes, one pt with secretory carcinoma and ETV6::NTRK3 fusion experienced a sustained response to larotrectinib. HER2 IHC2 + expression without gene amplification was observed in 15 pts. Two pts responded to trastuzumab deruxtecan (TDxd) after progression on first line therapy.

conclusionsThe impact of immunohistochemical or molecular markers on treatment selection and response was most pronounced in SDC. HER2 IHC2 + expression was observed across multiple subtypes, indicating that TDxd may represent a potential treatment option for more pts than previously anticipated. The impact of comprehensive genomic profiling on targeted treatment options is currently still modest.

Indexed as

Neoplasm Recurrence, LocalSalivary Gland NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm MetastasisRetrospective StudiesTertiary Care CentersBiomarkers, TumorComprehensive genomic profilingImmunohistochemical markersRetrospective analysisSalivary gland cancerTargeted treatment

Identifiers

PMID41593390
PMCPMC12847554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.